Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis

Limeng Wu1, Canhua Jiang2,3, Zhihui Zhu1, Yao Sun4, Tao Zhang1*

1 Department of Stomatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China, 2 Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China, 3 Research Center of Oral and Maxillofacial Tumor, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China, 4 Department of Radiation Oncology, CyberKnife Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People’s Republic of China

* drtzhang@126.com

Abstract

Background

Although programmed cell death-ligand 1 (PD-L1) has been recognized as a potential marker in several cancers, the relationship between PD-L1 expression and survival in patients with salivary gland carcinoma (SGC) has remained unclear. We aimed to evaluate the association of PD-L1 expression with clinicopathological features and prognosis in SGC patients.

Methods

The databases Ovid Medline, PubMed, Scopus, and EMBASE were searched for relevant studies that detected PD-L1 expression in SGC. The meta-analysis was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA), and the reporting recommendations for tumor marker prognostic studies (REMARK) was used to assess the quality of research eligible for this meta-analysis. Included studies were assessed using the Quality in Prognosis Studies (QUIPS) tool. Odds ratios (ORs) with 95% confidence interval (CI) were calculated to estimate the correlation between PD-L1 expression and clinicopathological features. Hazard ratios (HRs) with 95% CI were applied to assess the association between PD-L1 expression and survival outcomes of patients.

Results

A total of ten studies (including 952 patients with SGC) were evaluated. The meta-analysis showed that positive PD-L1 expression in SGC was significantly associated with male patients, older age, Tumor stage, lymph node metastasis, high pathological grade, and non-adenoid cystic carcinoma subtype. The pooled data demonstrated that high PD-L1 expression was associated with poor overall survival and disease-free survival. There was no
significant correlation between PD-L1 expression and progression-free survival or diseasespecific survival of SGC patients.

**Conclusion**

According to the meta-analysis, positive PD-L1 expression may play an important role as an effective marker of poor prognosis in patients with SGC. However, large-scale, prospective investigations are still needed to confirm the findings. The assessment of PD-L1 expression may aid in the personalized management of SGC.

**Introduction**

Salivary gland carcinomas (SGCs), with an incidence of 12–30 per one million people, are relatively rare malignancies, accounting for more than 0.5% of all malignancies and approximately 1%–8% of head and neck carcinomas worldwide [1–5]. SGCs presented with strong heterogeneity, which leads to different histological subtypes [6], there are more than 20 different pathological subtypes according to the World Health Organization. Thus, complex biological behaviors of SGCs presented greater differences in the clinical course. SGCs are generally slow-growing and characterized by frequent local recurrence and latent distant metastases. Surgical resection is the standard treatment for localized SGC [7], radiation and/or chemotherapy are considered in the adjuvant setting. However, the 5-year postoperative recurrence rate ranged from 25 to 46% [5, 8–10]. Predicting the outcome of SGC patients is challenging for clinicians due to the diversity of tumor behavior.

The programmed cell death ligand (PD-L1) is expressed in resting immune cells and various tumor cells. When the programmed death-1 (PD-1) molecule binds to the PD-L1 receptor ligand, a complex is formed that suppresses cytotoxic T cells, resulting in apoptosis and tumor escape. Overexpression of PD-L1 has been linked to a poor prognosis and outcome in malignant tumors such as breast cancer, gastrointestinal tract cancer, cholangiocarcinoma, and renal cell carcinoma [11–15]. However, the role of PD-L1 expression in SGC remains unclear. Several cohort studies showed that positive expression of PD-L1 was associated with poor survival of SGC patients [16–18]. However, other studies reported different outcomes [19, 20].

Since controversial conclusions remain, it is necessary to analyze to clarify the role of PD-L1 in SGC patients and obtain a universal conclusion to guide clinical practice.

In this study, we conducted a systematic review and meta-analysis to assess the relationships between PD-L1 expression and clinicopathological features of SGC patients, as well as the association between PD-L1 expression and SGC patient survival outcomes.

**Materials and methods**

**Search protocol**

A comprehensive literature search was conducted for potential articles on Ovid Medline, PubMed, Scopus, and EMBASE. The search strategies were based on combinations of the following keywords: “PD-L1, B7-H1, CD274, programmed cell death ligand 1”, “salivary gland, parotid gland, submandibular gland, sublingual gland, salivary duct, adenoid cystic, mucoepidermoid”, “tumor, neoplasm, cancer, carcinoma”, and “survival, prognostic, prognosis, outcome, mortality”. The search was limited to articles in the English language. Both published and unpublished studies were sought. The endpoint of the search was January 13, 2022.
search was re-run before the final analysis. This meta-analysis was performed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [21] and the reporting recommendations for tumor marker prognostic studies (REMARK) [22] were followed when we conducted and reported this meta-analysis. The proposal was registered a priori at the National Institute for Health Research, International Prospective Register of Systematic Reviews (PROSPERO; name: prognostic role of PD-L1 expression in patients with salivary gland carcinoma: a systematic review and meta-analysis; registration number: CRD42020183228). The review protocol was not published.

Selection of studies
Studies were considered eligible for inclusion if they satisfied the following criteria: (1) clinical cohort studies; (2) PD-L1 expression in the tumor tissues was detected by immunohistochemistry (IHC); (3) investigated the PD-L1 expression of SGC patients, included both positive and negative expression patients; (4) the relationships between PD-L1 expression and clinicopathological features, prognosis outcomes were depicted in the study; (5) provided information on the relationships of PD-L1 expression with survival parameters in patients with SGC or sufficient information for estimating the hazard ratio (HR).

Exclusion criteria were as follows: (1) studies reported in conference abstracts, reviews, or letters; (2) studies with insufficient data, no access to the full manuscript, reported published data, and non-English language publications.

Data extraction and quality assessment
Two reviewers separately screened the titles and abstracts of publications identified by the search strategy to exclude irrelevant research. Any discrepancies between the two reviewers were resolved by discussion and consensus. The two reviewers carefully examined the full manuscripts of potentially eligible articles to determine whether they should be included or not. Disagreements were resolved by discussion or consultation with a third reviewer. Microsoft Excel spreadsheet was used to record decisions. Data extraction was independently performed by 2 reviewers. Basic information of the studies such as first author, publication year, the origin of population, number of patients, and clinical and pathological characteristics of patients such as gender, age, subtype of SGC, TNM category, tumor grade, clinical stage, perineural invasion (PNI), vascular invasion (VI), margin status, treatment outcome, type of tissue for PD-L1 expression analysis, the cut-off value for PD-L1 positivity, and PD-L1 expression score were extracted.

Patient survival outcomes included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and disease-specific survival (DSS). OS is defined as the time interval between the date of primary treatment and the date of death or last follow-up; DFS is defined as the period of time without evidence of disease (i.e. persistence, recurrence or metastasis) after primary treatment; DSS is defined as the duration after primary treatment to death due to SGC; PFS is defined as the length of time during and after the primary treatment of SGC that the patient lives with the disease but it does not get worse. HR and the corresponding 95% confidential interval (CI) for patient survival data were extracted. For studies that showed survival data indirectly with a Kaplan-Meier curve, the methods utilized were described by Tierney et al. [23] to estimate. Disagreements were resolved by discussion or consultation with a third reviewer. Microsoft Excel spreadsheet was used to record data.

Risk of bias
Two reviewers independently assessed included studies for risk of bias using the Quality In Prognosis Studies (QUIPS) tool [24]. The QUIPS tool contains six domains: study
participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, statistical analysis and reporting. Each domain contains 3–7 prompting items and considerations, and each domain is rated as high, moderate, or low risk of bias considering the prompting items. The overall risk of bias for each study was categorized as low if the risk of bias was low in all domains, moderate if the risk of bias was deemed to have moderate in one to four domains, or high if the risk of bias was high in at least one domain. Any discrepancies were resolved by discussion and consensus.

### Statistical analysis

In this meta-analysis, all extracted data were processed using Stata software (version 15.0; Stata Corp LP, College Station, TX), R Studio (Version 1.2.1335; R Studio, Boston, MA). The relationships between PD-L1 expression and clinical and pathological parameters were evaluated using an odds ratio (OR) with 95% CIs. HR with 95% CI was used to assess the association between PD-L1 expression and the survival of SGC patients. Statistical heterogeneity among studies was assessed via the $\chi^2$ test and the $I^2$ test. We applied a random-effects model to calculate the pooled data if significant heterogeneity is detected ($P<0.1$ or $I^2>50\%$). Otherwise, a fixed-effects model was implemented. A $P$-value less than 0.05 was considered statistically significant.

For the heterogeneity of SGC (both subtype of SGCs and heterogeneity within one tumor tissue), different detection techniques, and cutoff values of PD-L1 expression, subgroup investigations were performed. Subgroup analysis, stratified by sample size (0-100/>100), the cutoff value for PD-L1 positivity (1%/5%), PD-L1 expression score (tumor proportion score/combined positivity score, TPS/CPS), tumor tissue used for PD-L1 express detection (whole tissue section/tissue microarrays), and HR estimation (reported/calculated), were performed. We applied a random-effects model to calculate the pooled data if significant heterogeneity is detected ($P<0.1$ or $I^2>50\%$). Otherwise, a fixed-effects model will be implemented. A $P$-value less than 0.05 was considered statistically significant. The sensitivity analyses were also conducted to assess the robustness of the results and to explore the impact of each single study on the overall effect.

### Results

### Search results

The process of literature search and study selection is presented in Fig 1. A total of 207 studies were retrieved from searches of databases, and 121 studies were excluded as duplicates. A total of 48 studies had evaluated PD-L1 expression in SGC. After examining the title and abstract, 14 reports were discarded. Subsequently, the full text of the remaining 34 studies was evaluated, and 24 studies were excluded owing to the following reasons: six studies were conference abstracts or case reports, five studies did not evaluate the association between PD-L1 expression and clinicopathological data [20, 25–28], eight studies did not provide survival information [29–36], four studies did not provide sufficient data for HR calculation [18, 37–39], and 1 study was overlapped [40]. The present meta-analysis includes 10 studies with 952 patients which matched the eligibility criteria [16, 17, 19, 41–47].

### Study characteristics

A total of 952 patients from 10 independent cohorts were diagnosed with SGC, with various primary site including major and minor salivary glands. All the included studies were retrospective and published between 2016 and 2021. The patient number of the studies ranged
from 30 to 219. The patients were enrolled from 5 different countries: Poland [19], Japan [16, 17, 41, 44, 45], Germany [42, 47], Australia [43], and China [46].

IHC was applied to detect the expression of the PD-L1 protein in all studies. The definitions of positive staining of PD-L1 were different among studies since there has been no consensus so far. In the studies by Szewczyk [19], Nakano [45], Higashino [41], Kesar [42], only the positive IHC stains in tumor cells were deemed valid. In the other five studies, positive stains in tumor cells and tumor-infiltrating mononuclear cells (TIMCs) were presented [16, 17, 44, 46, 47], and 4 studies counted both tumor cells and TIMCs as one of the positive staining [43, 44, 46, 47], and therefore, survival data from studies applying CPS and immune cells (ICs) score for positive PD-L1 expression were also pooled to investigate the prognostic roles. PD-L1 expression was defined positively when positive cells were with membranous and/or cytoplasmic staining. The cut-off value of PD-L1 positivity was 1% in seven studies [16, 41, 43–47], 5% in three studies [17, 19, 42].
Regarding the prognosis of SGC patients, seven studies provided data about the association between PD-L1 and OS [16, 17, 42–44, 46, 47], five studies provided data on the association between PD-L1 expression and DFS [16, 19, 44–46], two studies provided data on the association between PD-L1 expression and PFS [42, 47], and two studies provided data on the association between PD-L1 expression and DSS [41, 45]. More detailed information of the eligible studies was presented in Table 1.

### PD-L1 expression and clinicopathological features

PD-L1 overexpression was associated with male patients, older age, T stage, positive N, higher pathological grade, and non-adenoid cystic carcinoma (ACC) subtype (Table 2). There was no statistically significant correlation between PD-L1 expression and Clinical Stage, PNI, VI, surgical margin, or treatment failure (Table 2).

### Risk of bias in studies

The 10 included studies were assessed using the QUIPS tool (Fig 2). Three studies were deemed to have a low risk of bias for all domains [42, 44, 46]. The other studies were rated with “moderate risk” [16, 17, 19, 41, 43, 45, 47]. As to the study participation domain, studies with consecutive samples and adequate sample size were considered “low risk”. One manuscript was judged to be “moderate risk” due to representative cases selection for both tumor and normal tissues collection for further analyses [45]. In assessing the bias of study attrition domain, studies with complete follow-up data were identified as having “low risk of bias”.

### Table 1. Summary of the studies that examined the prognostic value of PD-L1 in SGC.

| Author      | Year | Country | No. of patients | The cut-off value for PD-L1 positive | No. of positive expression n (%) | Follow-up time (months) | Adjuvant treatment | Survival parameter |
|-------------|------|---------|-----------------|-------------------------------------|----------------------------------|-------------------------|-------------------|--------------------|
| Szewczyk    | 2019 | Poland  | 117             | >5% TC                              | 22 (18.8)                        | 31 (2–110)              | RT                | DFS                |
| Nakano      | 2019 | Japan   | 30              | >1% TC                              | 11 (36.7)                        | NA                      | NA                | DFS, DSS           |
| Harada      | 2018 | Japan   | 47              | >5% TC                              | 24 (51.1)                        | 88.8 (22–154)           | NA                | OS                 |
|             |      |         |                 | >5% TIMC                            | 20 (42.6)                        |                         | OS                |                    |
| Mukaigawa   | 2016 | Japan   | 219             | >1% TC                              | 50 (22.8)                        | 44.9 (0.4–221)          | NA                | OS, DSS            |
|             |      |         |                 | >1% TIMC                            | 28 (12.8)                        |                         | OS, DSS           |                    |
| Witte       | 2020 | Germany | 94              | >1% TPS                             | 61 (64.9)                        | 89.5 (12–240)           | RT, CHEMO         | DFS, OS            |
|             |      |         |                 | >1% CPS                             | 75 (79.8)                        |                         | DFS, OS           |                    |
|             |      |         |                 | >5% IC*                             | 25 (26.9)                        |                         | DFS, OS           |                    |
| Higashino   | 2020 | Japan   | 127             | >1% TC                              | 36 (28.3)                        | 38 (2–213)              | RT                | DFS                |
| Sato        | 2021 | Japan   | 73              | >1% TPS                             | 31 (42.0)                        | 64.1 (1.9–205)          | NA                | DFS, OS            |
|             |      |         |                 | >1% MIDS                            | 44 (60.0)                        |                         | DFS, OS           |                    |
|             |      |         |                 | >1% CPS                             | 46 (63.0)                        |                         | DFS, OS           |                    |
| Kesar       | 2020 | Germany | 84              | >5% TPS                             | 14 (17.5)                        | 55 (0–443)              | RT, CHEMO         | DFS, OS, PFS       |
| Guazzo      | 2021 | Australia | 52          | >1% CPS                             | 9 (17.3)                         | 52.3 (0.7–123)          | RT, CHEMO         | DFS, OS, PFS, M    |
| Fang        | 2021 | China   | 109             | >1% TPS                             | 47 (43.1)                        | 45.6 (7–115)            | RT, CHEMO         | DFS, OS, M, PFS   |
|             |      |         |                 | >1% CPS                             | 87 (79.8)                        |                         | DFS, OS           |                    |
|             |      |         |                 | >1% IC                              | 48 (44.0)                        |                         | DFS, OS           |                    |

* survival data were not available for HR estimation; TC, tumor cell; RT, radio therapy; DFS, disease-free survival; NA, not available; DSS, disease-specific survival; OS, overall survival; TIMC, tumor-infiltrating mononuclear cell; TPS, tumor proportion score; CHEMO, chemotherapy; U, univariate analysis; M, multivariate analysis; PFS, progression-free survival; CPS, combined positivity score; IC, immune cell.
utilized for PD-L1 express detection (tissue microarrays/ entire tissue slice), and cut-off values were graded as having a low risk of bias for prognostic factor measurement. A clear definition of the survival outcomes was considered as low risk of bias for the outcome measurement domain. Four studies presented both univariable and multivariable outcome [16, 42, 44, 46], one study provided the latter [45], these studies were rated as having low risk of bias for study confounding domain. For statistical analysis and reporting, direct presentation of data for survival outcome was rated as “low risk”.

### PD-L1 expression and survival outcomes

**Association between PD-L1 expression and OS of SGC patients.** Data on the relationship between PD-L1 expression and OS were extracted from seven studies including 678 patients [16, 17, 42–46, 47]. The heterogeneity was not significant ($I^2 = 0.0\%$, $p = 0.814$); therefore, a fixed-effects model was adopted. As shown in Fig 3A, the pooled data demonstrated that there was a significant correlation between PD-L1 expression and OS of SGC patients ($n = 7$, HR = 1.587, 95% CI = 1.175–2.144, $P = 0.003$). Subgroup analysis was carried out based on sample size, cut-off value, PD-L1 expression score, PD-L1 expression type, and HR estimation. The data showed that PD-L1 is a significant factor of poor OS in SGC patients in studies that included less than a hundred patients, defining PD-L1 positive as cut-off value >1, using TPS as PD-L1 expression, utilized whole tissue section for the investigation. Whereas meta-regression analysis showed that no subgroups contribute to the heterogeneity of OS (Table 3).

Four included studies presented data with PD-L1 expression based on CPS score and OS [43, 44, 46, 47]. The heterogeneity was not significant ($I^2 = 0.0\%$, $p = 0.908$); therefore, a fixed-effects model was adopted. The pooled data revealed that there was no correlation between CPS score and OS in SGC patients ($n = 4$, HR = 0.592, 95% CI = 0.343–1.022, $P = 0.060$, Fig 4A). Another four studies presented data with PD-L1 expression based on IC score and OS [16, 17, 44, 46]. The heterogeneity was not significant ($I^2 = 0.0\%$, $p = 0.438$); therefore, a fixed-effects model was adopted. The pooled data revealed that there was no correlation between IC score and OS in SGC patients ($n = 4$, HR = 1.068, 95% CI = 0.702–1.626, $P = 0.758$, Fig 4B).

### Table 2. Meta-analysis of PD-L1 expression and clinicopathological features in SGC patients.

| Clinical parameters | No. of studies (No. of patients) | OR (95%CI) | Model | Heterogeneity | Significance($P$) |
|---------------------|---------------------------------|------------|-------|---------------|------------------|
| Gender (Male&Female) | 7(614) [16, 17, 42–46] | 1.735(1.194–2.521) | Fixed | 27.50% | 0.219 0.004 |
| Age (Old&Young)* | 7(614) [16, 17, 42–46] | 1.536(1.063–2.218) | Fixed | 28.20% | 0.213 0.022 |
| T stage (T3T4&T1T2) | 8(811) [16, 19, 41–46] | 1.829(1.019–3.283) | Random | 56.60% | 0.024 0.043 |
| N stage (N+&N-) | 7(694) [16, 41–46] | 3.263(2.276–4.679) | Fixed | 0.00% | 0.462 0.000 |
| Clinical Stage (III+IV&I+II) | 2(120) [17, 44] | 2.115(0.720–6.212) | Random | 48.90% | 0.162 0.173 |
| Pathological Grade (H&L+M) | 4(449) [16, 41, 44, 45] | 7.248(4.335–12.118) | Fixed | 20.70% | 0.286 0.000 |
| PNI (P&N) | 4(453) [16, 41, 44, 46] | 1.460(0.596–3.577) | Random | 70.70% | 0.017 0.408 |
| VI (P&N) | 4(453) [16, 41, 44, 46] | 2.812(0.940–8.407) | Random | 78.80% | 0.003 0.064 |
| Surgical margin (P&N) | 4(272) [19, 43–45] | 1.043(0.577–1.885) | Fixed | 10.10% | 0.343 0.889 |
| Subtype (non-ACC&ACC) | 5(554) [16, 41, 42, 45, 47] | 7.714(1.509–39.442) | Random | 71.30% | 0.008 0.014 |
| Treatment Failure (P&N) | 3(194) [17, 19, 45] | 1.417(0.360–5.571) | Random | 72% | 0.028 0.618 |

* Cutoff value of age included 45,60,61,63,64,65 and 66 years old, according to the median age of the included studies; OR, odds ratio; T stage, tumor stage; N stage, node stage; H, high; L, low; M, medium; PNI, perineural invasion; VI, vascular invasion; N, negative; P, positive; ACC, adenoid cystic carcinoma

https://doi.org/10.1371/journal.pone.0272080.t002
**Fig 2. Risk of bias assessment using the Quality In Prognosis Studies (QUIPS) tool.**

https://doi.org/10.1371/journal.pone.0272080.g002

| Study                          | Study participation | Study attrition | Prognostic factor measurement | Outcome measurement | Study confounding | Statistical analysis and reporting | Overall |
|-------------------------------|---------------------|----------------|-------------------------------|---------------------|------------------|----------------------------------|---------|
| Szewczyk 2019                 | +                   | −              | +                             | +                   | −                | −                                | −       |
| Nakano 2019                   | −                   | −              | +                             | −                   | +                | −                                | −       |
| Harada 2018                   | +                   | +              | +                             | +                   | −                | −                                | −       |
| Mukaigawa 2016                | +                   | +              | +                             | −                   | +                | +                                | −       |
| Witte 2020                    | +                   | +              | +                             | +                   | −                | +                                | −       |
| Higashino 2020                | +                   | −              | +                             | +                   | −                | −                                | −       |
| Sato 2021                     | +                   | +              | +                             | +                   | +                | +                                | +       |
| Kesar 2020                    | +                   | +              | +                             | +                   | +                | +                                | +       |
| Guazzo 2021                   | +                   | +              | +                             | −                   | −                | −                                | −       |
| Fang 2021                     | +                   | +              | +                             | +                   | +                | +                                | +       |
Association between PD-L1 expression and DFS of SGC patients

Five studies with 548 patients provided the HRs for DFS \([16, 19, 44–46]\). The heterogeneity was not significant \((I^2 = 0.0\%, P = 0.499)\); therefore, a fixed-effects model was applied. The pooled HR demonstrated a significant correlation between PD-L1 expression and DFS \((n = 5, HR = 1.658, 95\% CI = 1.246–2.208, P = 0.001; \text{Fig 3B})\).

Two included studies presented data with PD-L1 expression based on CPS score and DFS \([44, 46]\). The heterogeneity was not significant \((I^2 = 0.0\%, p = 0.780)\); therefore, a fixed-effects model was adopted. The pooled data showed that there was no correlation between CPS score and DFS in SGC patients \((n = 2, HR = 0.707, 95\% CI = 0.409–1.221, P = 0.213, \text{Fig 4C})\).

Table 3. Subgroup analyses of survival outcomes based on different factors.

| Subgroup                              | No. of studies (No. of patients) | HR (95% CI)          | Model       | Heterogeneity | Significance (P) | Meta-regression (P) |
|---------------------------------------|----------------------------------|----------------------|-------------|---------------|------------------|---------------------|
| Total                                 | 7 (678)                          | 1.587 (1.175–2.144)  | Fixed       | 0.00%         | 0.814            | 0.003               |
| Sample size                           |                                  |                      |             |               |                  |                     |
| >100                                  | 2 (328)                          | 1.558 (0.998–2.432)  | Fixed       | 0.00%         | 0.564            | 0.051               |
| <100                                  | 5 (350)                          | 1.612 (1.073–2.422)  | Fixed       | 0.00%         | 0.624            | 0.022               |
| Cut-off value                         |                                  |                      |             |               |                  |                     |
| >1%                                   | 5 (547)                          | 1.682 (1.219–2.320)  | Fixed       | 0.00%         | 0.815            | 0.002               |
| >5%                                   | 2 (131)                          | 1.065 (0.458–2.475)  | Fixed       | 0.00%         | 0.523            | 0.884               |
| PD-L1 expression score                |                                  |                      |             |               |                  |                     |
| TPS                                   | 6 (626)                          | 1.593 (1.178–2.152)  | Fixed       | 0.00%         | 0.722            | 0.002               |
| CPS                                   | 1 (52)                           | 0.750 (0.008–67.903) | -           | -             | -                | 0.9                 |
| Type of PD-L1 expression              |                                  |                      |             |               |                  |                     |
| tissue microarrays                    | 1 (219)                          | 1.310 (0.625–2.744)  | -           | -             | -                | 0.474               |
| whole tissue section                  | 6 (459)                          | 1.649 (1.187–2.291)  | Fixed       | 0.00%         | 0.753            | 0.003               |
| HR estimation                         |                                  |                      |             |               |                  |                     |
| calculated                            | 3 (278)                          | 1.719 (1.005–2.940)  | Fixed       | 0.00%         | 0.924            | 0.048               |
| reported                              | 4 (400)                          | 1.531 (1.065–2.200)  | Fixed       | 0.00%         | 0.443            | 0.021               |

HR, hazard ratio; TPS, tumor proportion score; CPS, combined positivity score; CI: confidence interval.

https://doi.org/10.1371/journal.pone.0272080.t003
presented data with PD-L1 expression based on IC score and DFS \([16, 44, 46]\). The heterogeneity was not significant \((I^2 = 0.0\%, p = 0.937)\); therefore, a fixed-effects model was adopted. As shown in Fig 4D, the pooled data demonstrated that there was no association between IC score and DFS of SGC patients \((n = 3, HR = 0.921, 95\% CI = 0.604–1.403, P = 0.701)\).

**Association between PD-L1 expression and PFS of SGC patients.** Data on PD-L1 expression and PFS were retrieved from two included studies involving 178 patients \([42, 47]\). Because of significant heterogeneity \((I^2 = 66.8\%, p = 0.083)\), a random–effects model was applied. The pooled HR indicated that the correlation between PD-L1 expression and PFS was not significant \((n = 2, HR = 1.317, 95\% CI = 0.507–3.420, P = 0.572; \text{Fig 5A})\).

**Association between PD-L1 expression and DSS of SGC patients.** The DSS HRs were derived from two investigations including 157 patients. The heterogeneity was not significant \((I^2 = 0.0\%, p = 0.475)\); therefore, a fixed–effects model was applied. The pooled HR indicated that the correlation between PD-L1 expression and DSS was not significant \((n = 2, HR = 3.567, 95\% CI = 0.682–18.664, P = 0.132; \text{Fig 5B})\).

**Sensitivity analysis**
The sensitivity analyses were conducted to evaluate the reliability and stability of the results by removing each study one at a time. As shown in S1 Fig, the pooled ORs for gender, age, T
stage, N stage, pathological grade, and subtype (non-ACC&ACC) were highly credible. And the sensitivity analyses of the association of PD-L1 and OS and DFS were also performed, and the results of the sensitivity analysis demonstrated high credibility of the pooled HRs as well (S1 Fig). Because of the limited number of studies, we failed to conduct the sensitivity analyses in PFS and DSS. For the same reason, we failed to conduct the publication bias of survival outcomes.

Discussion

Because of the highly heterogeneous nature and variable clinical course of SGC, patients’ survival outcomes are hard to predict. The PD-L1/PD-1 signaling pathway is an important component of tumor immunosuppression, which can inhibit the activation of T lymphocytes and enhance the immune tolerance of tumor cells, thereby achieving tumor immune escape [48, 49]. Recent studies showed that pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1positive SGC [50, 51]. Other recent studies showed the effectiveness and safety of nivolumab for the treatment of SGC [26, 52]. All of these findings suggest that immune checkpoint inhibitors have clinical efficacy in patients with SGC. However, there is yet insufficient evidence to demonstrate a clear predictive role for PD-1/PD-L1 blockade therapy in SGC. This meta-analysis comprehensively and systematically assessed the relationship of PD-L1 expression with clinicopathological features and prognosis in patients with SGC.

In our analysis of clinicopathological features, it was found that men or elder patients with SGC having late tumor stage, lymph node metastasis, high pathological differentiation, or non-ACC subtype were more likely to exhibit high PD-L1 expression. There were no apparent relationships between positive PD-L1 expression and clinical stage, PNI, VI, surgical margin, or treatment failure. A recent meta-analysis performed by Tang et al. [53], included 886 participants and among which 6 studies, demonstrated that PD-L1 was highly expressed in female patients with oral squamous cell carcinoma (OSCC). In the same study, the author found that PD-L1 overexpression was associated with younger age in patients with oropharyngeal squamous cell carcinoma (OPSCC) according to 2 studies that included 212 patients. These findings have contradicted the results of our study. This study proposed that maybe the variant microenvironment of different cancer types and different cutoff values of age among studies
contribute to the differences. The molecular mechanism that accounts for this difference remains to be uncovered. Further studies are needed for investigating these.

He et al. [54] reviewed the PD-L1 expression of 2291 OSCC patients from 17 studies, and the results revealed that positive PD-L1 expression was significantly related to N stage. In the same meta-analysis, which included 18 researches with 2396 OSCC and OPSCC patients, the result showed that the positive rate in patients with late T stage was higher than that of early T stage based on 18 studies including 2396 OSCC and OPSCC patients; however, the difference was not statistically significant. Another meta-analysis that included 1501 OSCC and OPSCC patients from 12 studies examined the correlations between lymph node metastases and PD-L1 expression. The results indicated that there is a tendency between lymph node metastasis and increased PD-L1 expression [53]. The above meta-analysis both demonstrated that positive PD-L1 expression was associated with higher pathological grades. These findings were consistent with the results of our present study of the association between PD-L1 expression and T stage, N stage, and pathological grade in SGC patients.

Immune cell infiltration differs among SGC subtypes, Linxweiler et al. [55] demonstrate that levels of immune infiltration of SGCs were associated with mutation- and fusion-derived neoantigens. They discovered that salivary duct carcinomas (SDC) had significant levels of immune infiltrate, higher levels of T-cell dysfunction and mutational load. ACCs, on the other hand, have an immune-excluded microenvironment and low mutational load. Mucoepidermoid carcinomas (MEC) exhibited both immune-low and immune-high characteristics. Our result of positive PD-L1 expression in the non-ACC subtype is in line with data from Dou et al. [39] and Mosconi et al. [33] who focused on the ACC subtype and demonstrated nearly no PD-L1 expression in ACC. Mosconi et al. observed that immune tolerance phenotype tumors are accompanied by low or no PD-L1 expression in ACC [39]. Maybe the impaired IFN-γ response signal transduction in tumor cells could explain these observations to some extent [56]. A recent randomized phase 2 study [57] confirmed low levels of PD-L1 expression and CD8 infiltrating T-cells in patients with recurrent or metastatic ACC. A total of 20 patients in this study underwent pembrolizumab with or without radiation. The results showed that stable disease was more common in patients with demonstrable PD-L1 expression.

Pathological subtypes may influence the prognosis of SGC. For MEC, the OS rate of high-grade and low/intermediate-grade MEC at 5 years was 52% and 83% according to Chen et al. [58]. A recent study conducted by Chan et al. [59] indicated that treatment for MEC with adequate surgical resection and adjuvant radiation therapy yields excellent survival (5-year OS rate of 93.6%), irrespective of pathologic grade. The prognosis of ACC and acinic cell carcinoma (AcCC) is considered favorable as the OS rate at 5 years approaches 90% [60] and 97.2% [61], whereas 5-year OS was poor for carcinoma ex pleomorphic adenoma (Ca-ex-PA) and SDC at 68.5% [62] and 47.9% [63]. In our meta-analysis, three studies presented the data on the influence of pathological subtypes on survival. In the study by Fang 2021, high-grade MEC has been reported as not being an independent prognostic factor for OS or DFS [46]. In the study by Mukaigawa 2016, the histological type was not a significant predictive factor for poor OS, but Ca-ex-PA, SDC, and adenocarcinoma-not otherwise specified (AcNOS) presented worse 5-year OS compared to ACC according to univariate analysis [16]. According to their pathological subtype, Kesar et al. classified the samples as aggressive (ACC, AcNOS, SDC, and high-grade MEC) or non-aggressive (AcCC and low-and intermediate-grade MEC). In univariate analysis, the non-aggressive subtype characteristic was associated with a significantly improved OS and PFS. However, in multivariate analyses, aggressive histopathological subtype characteristic was not an independent prognostic variable [42].

The site of the primary tumor was also an important predictor of outcome in SGC patients. Park et al. investigated the survival outcome of 108 intermediate-grade SGC patients in their
study, from which the most common histologic type was MEC and ACC; the result suggested that a non-parotid primary site is an independent prognostic factor for poor RFS [64]. For ACC and SDC, patients with parotid gland tumors demonstrated more favorable survival outcomes [65, 66]. And a primary site in the submandibular gland was an independent prognostic factor for worse survival outcomes [63, 67]. The tumor site (major and minor salivary gland) did not affect survival in Ca-ex-PA patients [68]. In our meta-analysis, two studies presented the data on the influence of primary tumor sites on survival outcomes. In the study by Mukai-gawa 2016, the primary site of the major or minor salivary gland was not a predicted factor for DFS or OS [16]. According to the study by Fang 2021, the main histological types were high-grade MEC and SDC, a primary site in the parotid gland that was an independent prognostic factor for worse DFS and OS in patients with high-grade SGC [46]. The above conflicting results should be attributed to the heterogeneity of pathological subtypes and the grade of included cases. When investigating the prognosis of SGC, various risk factors, such as pathological subtypes, grades, and primary tumor location, should be considered simultaneously.

PD-L1 expression has been studied for its prognostic value in head and neck cancer (HNC) in various meta-analysis studies. Li et al. [69] analyzed the survival data of 2869 HNC patients, this meta-analysis showed that the positive expression of PD-L1 was associated with shorter OS and shorter DFS in patients from Asian countries/regions. They also discovered that positive PD-L1 expression was associated with a poor OS in patients with OSCC. This finding is consistent with a recent meta-analysis, which based on data from 26 studies involving 2532 cases, this study showed that PD-L1 overexpression could predict worse DSS and DFS in patients with OSCC [70]. Nevertheless, Yang et al. [71] analyzed survival data of 285 patients with advanced HNSCC patients in their meta-analysis; they found that patients with positive PD-L1 expression showed an improved PFS when compared to those with negative PD-L1 expression. Patel et al. [72] investigated survival outcome and tumor response with 1007 HNSCC patients from twelve studies, they concluded that patients expressing PD-L1 may have a better tumor response and OS. Jia et al. [73] reviewed 52 studies with 7127 HNC patients, they demonstrated that higher expression of PD-L1 correlated with better PFS. These investigations discovered that patients with PD-L1 expression may respond better to PD-L1 inhibitor therapy. Our study examined the survival data of 952 SGC patients from 10 cohort studies, and the findings revealed that PD-L1 expression was significantly associated with SGC patients’ OS and DFS. However, there was no significant correlation between PD-L1 expression and PFS or DSS of SGC patients.

According to the findings, positive PD-L1 expression may predict a poor prognosis in SGC patients. These findings would help to establish the rationale for the therapeutic potential of targeting the PD-1/PD-L1 pathway in SGC patients. Moreover, our Meta-analysis indicated that SGC with a high-pathological grade presented with high PD-L1 expression, and high PD-L1 expression indicate a poor prognosis. These results support the hypothesis that SGC with positive PD-L1 expression is more aggressive and has a poor prognosis, which is consistent with previous research. As a result, our findings may have clinical implications for guiding the optimal clinical use of PD-1/PD-L1 inhibitors in these patients. In this meta-analysis, we did not detect the relationship between PFS and positive PD-L1 expression in SGC patients. PFS is mainly used in patients with advanced staged or recurrent/metastatic cancer. However, the majority of our included studies were based on primary tumors, and only two studies included both primary and recurrent tumors [42, 47]. Two studies investigated DSS and PD-L1 expression in SGC patients [41, 45], and the pooled results presented no association between PD-L1 expression and DSS. These results may be attributed to the limited number of included studies, in which change in any included study should influence the pooled results.
Because there were fewer studies included, the link with PFS/DSS was not dominant. More research is required to clarify the results.

Different scores have been introduced for the assessment of PD-L1 expression. TPS/PD-L1 positivity has been widely used to assess the prognostic value for HNC patients in meta-analysis. He et al. [54] found that high PD-L1 expression in OSCC was not related to OS, Tang et al. [53] demonstrated that the higher PD-L1 expression in tumor cells indicated a better DFS of OPSCC, and Yang et al. [71] claimed that the positive PD-L1 expression might predict better PFS in patients with advanced HNSCC. Furthermore, in a randomized phase 3 clinical study for recurrent/metastatic HNSCC, TPS- and CPS-PD-L1 positive was employed as a predictor of responses to PD-1/PD-L1 inhibitors [74, 75]. However, the significance of PD-L1 expression according to these scores in SGC remains unclear. One published clinical trial data for SGC set PD-L1 expression on ≥1% of tumor or stroma cells as positive expression. This study included 26 patients treated with pembrolizumab for unresectable/metastatic PD-L1 positive SGC. The objective response rate was 12%, and 12 patients (46%) had stable disease [50]. The other phase 2 study used ≥1% of tumor cells as positive PD-L1 expression in their study. This study included recurrent or metastatic ACC patients, and 60% patients underwent pembrolizumab treatment presented with stable disease [57]. In patients with advanced PD-L1 positive SGC, a PD-1 inhibitor with a manageable safety profile demonstrated potential antitumor efficacy. Our meta-analysis demonstrated that positive PD-L1 expression based on TPS, rather than CPS or IC scores indicate an important prognostic role and should be a better promising target for immunooncologic treatment.

There were no subgroup parameters that contributed to the study’s heterogeneity. Our subgroup analysis indicated that >1% may be a better cut-off value for PD-L1 positivity in SGC patients. Tissue microarray can obtain high throughput information of histomorphology and protein expression on a single section with a small tissue core. Whereas, for the reason of intertumoral heterogeneity, a small tissue sample does not represent the overall expression of PD-L1 [76]. Our study suggests that the whole tissue section should be the optimal tissue for the investigation of PD-L1 expression in SGC patients.

Some limitations of this meta-analysis must be considered when interpreting the results. First, studies on heterogeneity limit the validity of outcomes, which might be due to the diversity of pathological subtypes, intratumoral heterogeneity of SGC, different primary cancer sites and stages, and different treatment regimens. A more comprehensive analysis, such as individual participant data meta-analysis with large sample size studies, should be performed to improve the quality of data and confirm the findings. Second, although the prevalence of SGC is relatively low, the sample size with 10 studies that included 952 patients were not favorable for effective pooled analyses, high-quality multicenter clinical trials should be conducted to verify our conclusions. Third, all included studies were retrospective, which presented a relatively inferior level of evidence; data from prospective studies will be needed to gain certainty in the evidence.

Conclusions

In summary, our meta-analysis indicated that positive PD-L1 expression was significantly associated with certain clinicopathological features, including gender, age, T stage, lymph node metastasis, and pathological grade and type in patients with SGC. Higher expression of PD-L1 was associated with poor OS and DFS of SGC patients. Thus, our findings imply that elevated PD-L1 expression may be a significant predictor of poor prognosis in SGC patients. Large-scale, prospective studies are still needed to confirm the findings. The assessment of PD-L1 expression may aid in the personalized management of SGC.
Supporting information

S1 Table. Search strategy of database.
(DOCX)

S2 Table. PRISMA checklist.
(DOCX)

S3 Table. Clinicopathological features of included studies.
(XLSX)

S4 Table. Survival parameters of included studies.
(XLSX)

S1 Fig. Sensitivity analysis.
(DOCX)

Acknowledgments

We would like to thank the researchers and study participants for their contributions.

Author Contributions

Conceptualization: Limeng Wu, Canhua Jiang.

Data curation: Limeng Wu, Zhihui Zhu, Yao Sun, Tao Zhang.

Formal analysis: Limeng Wu, Canhua Jiang.

Methodology: Limeng Wu, Canhua Jiang, Zhihui Zhu.

Software: Limeng Wu.

Supervision: Canhua Jiang, Tao Zhang.

Writing – original draft: Limeng Wu, Tao Zhang.

Writing – review & editing: Limeng Wu, Canhua Jiang, Zhihui Zhu, Tao Zhang.

References

1. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999; 120(6):834–40. https://doi.org/10.1016/S0194-5998(99)70323-2 PMID: 10352436.

2. Boukheris H, Curtis RE, Land CE, Dores GM. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):2899–906. https://doi.org/10.1158/1055-9965.EPI-09-0638 PMID: 19861510.

3. Bell D, Hanna EY. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep. 2012; 14(2):166–74. https://doi.org/10.1007/s11912-012-0220-5 PMID: 22246609.

4. Tamaki T, Dong Y, Ohno Y, Sobue T, Nishimoto H, Shibata A. The burden of rare cancer in Japan: application of the RARECARE definition. Cancer Epidemiol. 2014; 38(5):490–5. https://doi.org/10.1016/j.canep.2014.07.014 PMID: 25155209.

5. Szewczyk M, Golusinski P, Pazdrowski J, Pienkowski P, Golusinski WJ. Management of clinically negative neck in salivary gland cancers—elective neck dissection, irradiation, or surveillance? Contemp Oncol (Pozn). 2019; 23(3):169–73. https://doi.org/10.5114/wo.2019.89245 PMID: 31798333.

6. Hosni A, Huang SH, Goldstein D, Xu W, Chan B, Hansen A, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol. 2016; 54:75–80. https://doi.org/10.1016/j.oraloncology.2015.11.023 PMID: 26723908.
7. Lewis AG, Tong T, Maghami E. Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland. Otolaryngol Clin North Am. 2016; 49(2):343–80. https://doi.org/10.1016/j.otc.2015.11.001 PMID: 27040585.

8. Yu GY, Ma DQ. Carcinoma of the salivary gland: a clinicopathologic study of 405 cases. Semin Surg Oncol. 1987; 3(4):240–4. https://doi.org/10.1002/ssu.2980030405 PMID: 3432840.

9. Johnston ML, Huang SH, Waldron JN, Atanau EG, Chan K, Cummings BJ, et al. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head Neck. 2016; 38 Suppl 1:E820–6. https://doi.org/10.1002/hed.24107 PMID: 25916947.

10. Guntinas-Lichius O, Thielker J, Robbins KT, Olsen KD, Shaha AR, Makitie AA, et al. Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review. Head Neck. 2020. https://doi.org/10.1002/hed.26541 PMID: 33169420.

11. Huang B, Chen L, Bao C, Sun C, Li J, Wang L, et al. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. Oncol Targets Ther. 2015; 8:2617–25. https://doi.org/10.2147/OTT.S91025 PMID: 26451118.

12. Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015; 8(9):14595–603. PMID: 26628942.

13. Li X, Li M, Lian Z, Zhu H, Kong L, Wang P, et al. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Target Oncol. 2016; 11(6):753–61. https://doi.org/10.1007/s11523-016-0451-8 PMID: 27422733.

14. Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017; 14(1):250–6. https://doi.org/10.3892/ol.2017.6105 PMID: 28693161.

15. Dong Z, Liao B, Shen W, Sui C, Yang J. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma. Dig Dis Sci. 2020; 65(2):480–8. https://doi.org/10.1007/s10620-019-05787-0 PMID: 31410753.

16. Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fuji S. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. Journal of surgical oncology. 2016; 114(1):36–43. https://doi.org/10.1002/jso.24266 PMID: 27111278.

17. Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018; 18(1):156. https://doi.org/10.1186/s12885-018-4069-3 PMID: 29409471.

18. Vital D, Ikenberg K, Moch H, Rossle M, Huber GF. The expression of PD-L1 in salivary gland carcinomas. Scientific reports. 2019; 9(1):12724. https://doi.org/10.1038/s41598-019-49215-9 PMID: 31484986.

19. Szewczyk M, Marszalek A, Sygut J, Golusinski P, Golusinski W. Prognostic markers in salivary gland cancer and their impact on survival. Head Neck. 2019; 41(9):3338–47. https://doi.org/10.1002/hed.25857 PMID: 31246357.

20. Xu B, Jungbluth AA, Frosina D, Alzumaili B, Aleynick N, Sildokowska E, et al. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology. 2019; 75(5):672–82. https://doi.org/10.1111/his.13944 PMID: 31237963.

21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264–9, W64. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 PMID: 19622511.

22. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012; 10:51. https://doi.org/10.1186/1741-7015-10-51 PMID: 22642691.

23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. https://doi.org/10.1186/1745-6215-8-16 PMID: 17555582.

24. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013; 158(4):280–6. https://doi.org/10.7326/0003-4819-151-4-201302190-00009 PMID: 23420236.

25. Hamza A, Roberts D, Su S, Weber RS, Bell D, Ferrarotto R. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol. 2019; 40:49–52. https://doi.org/10.1016/j.anndiagpath.2019.04.001 PMID: 30978575.

26. Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, et al. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Scientific reports. 2020; 10(1):16988. https://doi.org/10.1038/s41598-020-73965-6 PMID: 33046752.
27. Hiss S, Eckstein M, Segschneider P, Mansopoulos K, Iro H, Hartmann A, et al. Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AcIC) of the Salivary Glands. Cancers (Basel). 2021; 13(5). https://doi.org/10.3390/cancers13050365 PMID: 33669036.

28. Schvartsman G, Bell D, Rubin ML, Tetzlaff M, Hanna E, Lee JJ, et al. The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021; 43(4):1213–9. https://doi.org/10.1002/hed.26587 PMID: 33576119.

29. Sridharan V, Gjini E, Liao X, Chau NG, Haddad R, Sevrgnini M, et al. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016; 4(8):679–87. https://doi.org/10.1158/2326-6066.CIR-16-0031 PMID: 27312343.

30. Haderlein M, Scherl C, Semrhau S, Lettmayr S, Hecht M, Erber R, et al. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma: A monocentric clinicopathologic analysis. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2017; 193(11):961–70. https://doi.org/10.1007/s00066-017-1196-8 PMID: 28828498.

31. Mosconi C, Arantes DAC, Goncalves AS, Alencar RCG, Oliveira JC, Silva TA, et al. Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. Arch Oral Biol. 2017; 83:55–62. https://doi.org/10.1016/j.archoralbio.2017.07.004 PMID: 28711734.

32. Gargano SM, Senarathne W, Feldman R, Fiorento E, Stafford P, Swensen J, et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019; 8(17):7322–9. https://doi.org/10.1002/cam4.2602 PMID: 31609094.

33. Mosconi C, de Arruda JAA, de Farias ACR, Oliveira GAO, de Paula HM, Fonseca FP, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019; 88:95–101. https://doi.org/10.1016/j.oraloncology.2018.11.028 PMID: 30616805.

34. Chatzopoulos K, Collins AR, Sotiriou S, Keyne MG, Visscher DW, Rivera M, et al. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head Neck Pathol. 2020; 14(4):951–65. https://doi.org/10.1007/s12105-020-01163-x PMID: 32350809.

35. Steiniche T, Ladekarl M, Georgsen JB, Andreasen S, Busch-Sorensen M, Zhou W, et al. Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. Future Sci OA. 2020; 6(6):FSO616. https://doi.org/10.2144/fsoa-2020-0063 PMID: 32983568.

36. Kuchar M, Strizova Z, Capkova L, Komarc M, Skrivan J, Bartunkova J, et al. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. Biomedicines. 2021; 9(2). https://doi.org/10.3390/biomedicines9020097 PMID: 33498270.

37. Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017; 10:2983–92. https://doi.org/10.2147/OTT.S134589 PMID: 28652780.

38. Chen W, Fung AS, McIntyre JB, Simpson R, Afzal AR, Hao D, et al. Assessment Of Tumour Infiltrating Lymphocytes And Pd-1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland. Clin Invest Med. 2021; 44(1):E38–41. https://doi.org/10.25011/cim.v44i1.35218 PMID: 33743575.

39. Dou S, Li R, He N, Zhang M, Jiang W, Ye L, et al. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication. Front Immunol. 2021; 12:618367. https://doi.org/10.3390/immunolres9020097 PMID: 33498270.

40. Sato F, Akiba J, Kawahara A, Naito Y, Ono T, Takase Y, et al. The expression of programmed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. J Oral Pathol Med. 2018; 47(7):683–90. https://doi.org/10.1111/jop.12722 PMID: 29719073.

41. Higashino M, Kawata R, Nishikawa S, Terada T, Haginomori SI, Kurisu Y, et al. Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma. Acta Otolaryngol. 2020; 140(2):175–80. https://doi.org/10.1080/00016489.2019.1683604 PMID: 31944154.

42. Kesar N, Winkelmann R, Oppermann J, Ghanaati S, Martin D, Neumayer T, et al. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncol. 2020; 111:104931. https://doi.org/10.1016/j.oraloncology.2020.104931 PMID: 32736208.

43. Guazzo E, Cooper C, Wilkinson L, Feng S, King B, Simpson F, et al. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck. 2021; 43(3):768–77. https://doi.org/10.1002/hed.26529 PMID: 33169486.

44. Sato F, Ono T, Kawahara A, Matsuo K, Kondo R, Sato K, et al. Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. Laryngoscope. 2021; 131(5):E1481–E8. https://doi.org/10.1002/lary.29120 PMID: 33022760.
45. Nakano T, Takizawa K, Uezato A, Taguchi K, Toh S, Masuda M. Prognostic value of programmed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol. 2019; 90:30–7. https://doi.org/10.1016/j.oraloncol.2019.01.015 PMID: 30846173.

46. Fang Q, Wu Y, Du W, Zhang X, Chen D. Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma. Front Oncol. 2021; 11:701181. https://doi.org/10.3389/fonc.2021.701181 PMID: 34513680.

47. Witte HM, Gebauer N, Lappohn D, Umathum VG, Riecke A, Arndt A, et al. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. Cancers (Basel). 2020; 12(4). https://doi.org/10.3390/cancers12040873 PMID: 32260165.

48. Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, et al. Mechanisms regulating PD-L1 expression in tumor and immune cells. J Immunother Cancer. 2019; 7(1):305. https://doi.org/10.1186/s40425-019-0770-2 PMID: 31730010.

49. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18(1):10. https://doi.org/10.1186/s12943-018-0928-4 PMID: 30646912.

50. Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SY, Gilbert J, et al. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018; 41(1):1083–8. https://doi.org/10.1097/COC.0000000000000429 PMID: 29462123.

51. Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clin Cancer Res. 2020; 26(4):837–45. https://doi.org/10.1158/1078-0432.CCR-19-2214 PMID: 31796519.

52. Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fuji T, et al. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. International journal of clinical oncology. 2021; 26(3):494–506. https://doi.org/10.1007/s10147-020-01829-0 PMID: 32191460.

53. Tang H, Zhou X, Ye Y, Zhou Y, Wu C, Xu Y. The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. Pathol Res Pract. 2020; 216(1):152768. https://doi.org/10.1016/j.prp.2019.152768 PMID: 31837864.

54. Ho J, Chen XF, Xu MG, Zhao J. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. Arch Oral Biol. 2020; 114:104717. https://doi.org/10.1016/j.archoralbio.2020.104717 PMID: 32344357.

55. Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG, et al. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Cancers Differ by Subtype. Clin Cancer Res. 2020; 26(12):2659–70. https://doi.org/10.1158/1078-0432.CCR-19-3758 PMID: 32906100.

56. Theelen W, Kuijman T, Schulze K, Zou W, Krijgsman O, Peters D, et al. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer. PLoS One. 2019; 14(5):e0216864. https://doi.org/10.1371/journal.pone.0216864 PMID: 31125352.

57. Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, et al. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. International journal of radiation oncology, biology, physics. 2021; 109(1):134–44. https://doi.org/10.1016/j.ijrobp.2020.08.018 PMID: 32781104.

58. Chen AM, Lau VH, Farwell DG, Luu Q, Donald PJ. Mucopidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome. Laryngoscope. 2013; 123(12):3049–55. https://doi.org/10.1002/lary.24238 PMID: 23754320.

59. Chan SA, Van Abel KM, Lewis JE, Routman DM, Garcia JJ, Karp EE, et al. Mucopidermoid carcinoma of the parotid gland: Twenty-year experience in treatment and outcomes. Head Neck. 2021; 43 (9):2663–71. https://doi.org/10.1002/hed.26735 PMID: 33939193.

60. Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018; 41(1):1083–8. https://doi.org/10.1097/COC.0000000000000429 PMID: 29462123.

61. Pandey R, Sengupta S, Khan MN, Baredes S, Eloy JA. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope. 2014; 124 (1):172–8. https://doi.org/10.1002/lary.24231 PMID: 23754708.

62. Gupta A, Koochakzadeh S, Neskey DM, Nguyen SA, Lentsch EJ. Carcinoma ex pleomorphic adenoma: A review of incidence, demographics, risk factors, and survival. American journal of otolaryngology. 2019; 40(6):102279. https://doi.org/10.1016/j.amjoto.2019.102279 PMID: 31471126.
63. Ran J, Zou H, Li X, Guo F, Xu W, Han W. A population-based competing risk survival analysis of patients with salivary duct carcinoma. Ann Transl Med. 2020; 8(21):1355. https://doi.org/10.21037/atm-20-1849 PMID: 33313100.

64. Park GC, Roh JL, Cho KJ, Jung YG, Lee HW, Kim TG, et al. Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma. Oncology. 2018; 94(2):125–32. https://doi.org/10.1159/000484411 PMID: 29151106.

65. Luksic I, Baranovic S, Suton P, Gerbl D. Adenoid cystic carcinoma of the head and neck: a single-institution’s analysis of 45 consecutive cases over a 29-year period. Oral surgery, oral medicine, oral pathology and oral radiology. 2016; 122(2):152–7. https://doi.org/10.1016/j.oooo.2016.03.007 PMID: 27234852.

66. Otsuka K, Imanishi Y, Tada Y, Kawakita D, Kano S, Tsukahara K, et al. Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients. Annals of surgical oncology. 2016; 23(6):2038–45. https://doi.org/10.1245/s10434-015-5082-2 PMID: 26790669.

67. Kawakita D, Murase T, Ueda K, Kano S, Tada Y, Tsukahara K, et al. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan. International journal of clinical oncology. 2020; 25(10):1774–85. https://doi.org/10.1007/s10147-020-01731-9 PMID: 32613404.

68. Li J, Wang P, Xu Y. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. PLoS One. 2017; 12(6):e0179536. https://doi.org/10.1371/journal.pone.0179536 PMID: 28604812.

69. Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2018; 86:81–90. https://doi.org/10.1016/j.oraloncology.2018.09.016 PMID: 30400925.

70. Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856–67. https://doi.org/10.1056/NEJMoa1602252 PMID: 27718784.

71. Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, et al. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform LungScape cohort. Mod Pathol. 2020; 33(5):792–801. https://doi.org/10.1038/s41379-019-0383-9 PMID: 31740722.